Current Edition


Respiratory Disease Diagnosis and Testing Beyond COVID-19

Over the last year, the COVID-19 pandemic has placed healthcare for respiratory medicine firmly in the global spotlight. But even before this, over half a …

Continue Reading →

AstraZeneca won’t submit lung drug for COPD after 2nd study miss

AstraZeneca no longer plans to seek approval of its new respiratory biologic Fasenra in chronic obstructive pulmonary disease (COPD) after the second of two Phase 3 …

Continue Reading →

Owlstone Medical’s Breath Biopsy Platform integrated into GSK’s Phase II Respiratory Disease Clinical Trial

Owlstone Medical Ltd, a diagnostics company developing a breathalyzer for disease, today announced that GSK, a world leader in respiratory, will incorporate Owlstone Medical’s Breath …

Continue Reading →

GSK study shows COPD ‘superiority’ for Anoro Ellipta versus Stiolto Respimat

GlaxoSmithKline’s (GSK) study showed that Anoro Ellipta is more effective than Stiolto Respimat in improving lung function in patients with chronic obstructive pulmonary disease (COPD). …

Continue Reading →